Clinical trial
The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With…
NCT00379600 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00379600 |
|---|---|
| Title | The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis |
| Official title | A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | rosiglitazone XR |
| Enrollment | 96 |
| Start date | Nov 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 22, 2006 |
| Last update posted | Oct 26, 2016 |
| Countries | Lithuania, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: